Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., will deliver a presentation on Tuesday, August 12, 2025, at 2:00 p.m. EST.
Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.ceribell.com.
Ceribell (Nasdaq: CBLL), un'azienda di tecnologia medica specializzata nella diagnosi e gestione delle condizioni neurologiche, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Crescita di Canaccord Genuity. La CEO e cofondatrice dell'azienda, Jane Chao, Ph.D., terrà una presentazione martedì 12 agosto 2025 alle 14:00 EST.
Gli investitori potranno accedere sia alla versione in diretta che a quella registrata della presentazione tramite il sito web delle relazioni con gli investitori dell'azienda all'indirizzo investors.ceribell.com.
Ceribell (Nasdaq: CBLL), una empresa de tecnología médica especializada en el diagnóstico y manejo de condiciones neurológicas, ha anunciado su participación en la 45ª Conferencia Anual de Crecimiento de Canaccord Genuity. La CEO y cofundadora de la compañía, Jane Chao, Ph.D., ofrecerá una presentación el martes 12 de agosto de 2025 a las 2:00 p.m. EST.
Los inversionistas podrán acceder tanto a la versión en vivo como a la grabada de la presentación a través del sitio web de relaciones con inversionistas de la compañía en investors.ceribell.com.
Ceribell (나스닥: CBLL)은 신경학적 상태 진단 및 관리에 특화된 의료 기술 회사로, Canaccord Genuity 제45회 연례 성장 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO이자 공동 창립자인 Jane Chao 박사가 2025년 8월 12일 화요일 오후 2시(동부 표준시)에 발표를 진행할 예정입니다.
투자자들은 회사의 투자자 관계 웹사이트인 investors.ceribell.com을 통해 발표의 생중계 및 녹화본에 모두 접속할 수 있습니다.
Ceribell (Nasdaq : CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic et la gestion des troubles neurologiques, a annoncé sa participation à la 45e conférence annuelle sur la croissance de Canaccord Genuity. La PDG et cofondatrice de la société, Jane Chao, Ph.D., fera une présentation le mardi 12 août 2025 à 14h00 EST.
Les investisseurs pourront accéder aux versions en direct et en différé de la présentation via le site web des relations investisseurs de la société à l'adresse investors.ceribell.com.
Ceribell (Nasdaq: CBLL), ein Medizintechnologieunternehmen, das sich auf die Diagnose und Behandlung neurologischer Erkrankungen spezialisiert hat, hat seine Teilnahme an der 45. jährlichen Wachstumskonferenz von Canaccord Genuity angekündigt. Die CEO und Mitgründerin des Unternehmens, Jane Chao, Ph.D., wird am Dienstag, den 12. August 2025, um 14:00 Uhr EST eine Präsentation halten.
Investoren können sowohl die Live- als auch die aufgezeichnete Version der Präsentation über die Investor-Relations-Website des Unternehmens unter investors.ceribell.com aufrufen.
- None.
- None.
SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Canaccord Genuity 45th Annual Growth Conference. The presentation will take place on Tuesday, August 12, 2025, at 11:00 a.m. Pacific Standard Time / 2:00 p.m. Eastern Standard Time.
Event: Canaccord Genuity 45th Annual Growth Conference
Date: Tuesday, August 12, 2025
Time: 11:00 a.m. PST / 2:00 p.m. EST
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detecting suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When is Ceribell (CBLL) presenting at the Canaccord Genuity Growth Conference?
Who will be presenting for Ceribell at the Canaccord Conference?
How can investors watch Ceribell's Canaccord Conference presentation?
What does Ceribell (CBLL) specialize in?
